Printer Friendly

ADVANCED TISSUE SCIENCES PRESENTS DATA SHOWING SKIN2 TOXICITY TESTING PRODUCT CORRELATES STRONGLY WITH ANIMAL TESTING METHODS

 ADVANCED TISSUE SCIENCES PRESENTS DATA SHOWING SKIN2 TOXICITY
 TESTING PRODUCT CORRELATES STRONGLY WITH ANIMAL TESTING METHODS
 LA JOLLA, Calif., Feb. 27 /PRNewswire/ -- Scientists from Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATISA) presented results of correlation studies between Advanced Tissue Sciences Skin2(TM) Dermal and Full Thickness Model toxicity testing products and in vivo skin and eye screening tests at the Society of Toxicology Conference in Seattle this week. The in vivo skin and eye tests, such as the Draize test, are the industry standard toxicity tests which use rabbits to screen compounds in new household products, cosmetics, petrochemicals and pharmaceuticals. Scientists presented data showing that the results obtained using the in vivo Skin2 products correlated strongly with the live animal screening tests, according to Gail K. Naughton, Ph.D., executive vice president and chief operating officer of Advanced Tissue Sciences.
 "The four presentations included data comparing Skin2 with the Draize eye irritant test and with standard skin tests used by the industry today," Naughton said. "In all areas the correlation data were strong. In fact, in one study, the correlation coefficient, or R value, of the tests was .86, far superior to published R values for other in vitro testing methods which have generally not exceeded the range of .40 to .50.
 "These results indicate that the Skin2 products provide a useful and accurate in vitro test to screen the irritancy potential of compounds."
 The Skin2 Full Thickness and Dermal Model products are laboratory grown human skin cultured on a three-dimensional nylon mesh framework. The dermal fibroblasts and epidermal keratinocytes used in the manufacture of Skin2 are derived from neonatal foreskin tissue obtained during routine infant circumcision. The Skin2 products are designed to provide a rapid, reliable and cost-effective screening of compounds for both harmful and beneficial effects, including toxicity, irritation and metabolic effects.
 The Skin2 products were tested with a wide array of product types, including cosmetics, shampoos, industrial solvents, alcohols, metals, pesticides and antimicrobial preservatives. A battery of endpoints (MTT cell viability assay, lactate dehydrogenase enzyme release and inflammatory mediator-PGE2 release) were measured, representing final common pathways of skin or eye response to diverse test materials. In all instances, scientists obtained dose-dependent toxicity curves that correlated favorably with the standard toxicity screening methods which use animals.
 Skin2 was introduced in November 1990 and is produced in Advanced Tissue Sciences' La Jolla manufacturing facility. It is distributed by the company in the United States and through Janssen Biotech N.V. in Europe, Oriental Yeast Co. Ltd. in Japan and Pentachem Enterprises Co. in Taiwan.
 "The results presented support our belief that the Skin2 products are a significant advance in the worldwide effort to develop an alternative product testing method that is quicker and more cost effective, while at the same time producing results that are relevant to the human system," Naughton added.
 Advanced Tissue Sciences is engaged in the growth of human tissue outside the body. The company is developing its proprietary three- dimensional culture system for potential therapeutic and laboratory applications.
 -0- 2/27/92
 /CONTACT: Alana B. Wheeler of Advanced Tissue Sciences, 619-450-5714; or Linda Seaton or Richard Keatinge of The Gable Group, 619-234-1300, for Advanced Tissue Sciences/
 (ATISA) CO: Advanced Tissue Sciences Inc. ST: California IN: MTC SU:


JL -- SD001 -- 3115 02/27/92 09:16 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 27, 1992
Words:550
Previous Article:BALLANTINE BOOKS RECALLS GREAT CAKES COOKBOOK
Next Article:LAWYERS TITLE CORPORATION ANNOUNCES LETTER OF INTENT TO PURCHASE ASSETS OF LTIC ASSOC. INC. OF NEW YORK CITY
Topics:


Related Articles
IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO
ADVANCED TISSUE SCIENCES INC. REPORTS SECOND QUARTER RESULTS
PROCTER & GAMBLE DEVELOPS NEW, NON-ANIMAL PRODUCT SAFETY TEST USING ADVANCED TISSUE SCIENCES' TECHNOLOGY
ADVANCED TISSUE SCIENCES INC. REPORTS 1992 RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS FIRST QUARTER RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS SECOND QUARTER RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS THIRD QUARTER RESULTS
ADVANCED TISSUE SCIENCES ANNOUNCES FIRST QUARTER RESULTS
ADVANCED TISSUE SCIENCES ANNOUNCES SECOND QUARTER RESULTS
Advanced Tissue Sciences to Discontinue Sales of Skin2(R) Testing Kits; Company to Focus Exclusively on Therapeutic Products

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters